FDA MedWatch Safety AlertsOriginal article
Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine
RegulatoryCetirizine Hydrochloride Tablets USP 5 mgRanitidineNegative
AI Analysis
Summary
Unique Pharmaceutical Laboratories issued a voluntary nationwide recall of four lots of Cetirizine Hydrochloride Tablets USP 5 mg due to potential cross contamination with Ranitidine. The recall was announced on July 18, 2026 and extends to the consumer level.
Outcome Details
Voluntary recall of four lots of Cetirizine Hydrochloride Tablets USP 5 mg due to potential cross contamination with Ranitidine
Importance:4/10
Sentiment:
-0.80
product recallcross contaminationmanufacturing issueFDA MedWatchconsumer safety
Related Companies
Read the original article
Published by FDA MedWatch Safety Alerts on July 20, 2026 4:00 AM